Results 81 to 90 of about 26,226 (199)

The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes

, 2008
Alex C Spyropoulos1, Sharyl Magnuson1, Sei Keng Koh21Clinical Thrombosis Center, Lovelace Medical Center, Albuquerque, NM, USA; 2Department of Pharmacy, Singapore General Hospital, SingaporeAbstract: Heparin-induced thrombocytopenia (HIT) is an ...
Sharyl Magnuson, Alex C Spyropoulos, Sei Keng Koh   +2 more
core  

Thromboprophylaxis with fondaparinux in high-risk postoperative patients with renal insufficiency [PDF]

, 2014
Fondaparinux is an antithrombin-dependent factor Xa inhibitor that is used for thromboprophylaxis of patients undergoing hip fracture surgery, hip or knee replacement, or abdominal surgery.
Gonzalez, Daniel, Hester, Willie, Ortel, Thomas L., Fry, Caitlyn, Inman, Brant A., Cohen-Wolkowiez, Michael   +5 more
core   +1 more source

Maculopathy after long-term use of fondaparinux, a heparin mimetic and heparanase inhibitor

American Journal of Ophthalmology Case Reports
Purpose: To report maculopathy associated with the long-term use of fondaparinux, a heparin mimetic and inhibitor of the extracellular matrix enzyme, heparanase.
Benjamin R. Lin, Erick Rivera-Grana, Wenting Zhou, Mark Barakat, Philip J. Rosenfeld, Janet L. Davis   +5 more
doaj   +1 more source

Comparison of efficacy of nadroparin and fondaparinux sodium for prevention of deep vein thromboembolism in lower extremities after total hip arthroplasty and total knee arthroplasty: a retrospective study of 592 patients

BMC Surgery
Objectives To compare the efficacy of nadroparin and fondaparinux sodium for prevention of deep vein thromboembolism (DVT) in lower extremities after total hip arthroplasty (THA) and total knee arthroplasty (TKA).
Xiang Gao, Xiaowei Jin, Rui Huang, Zhenxing Li, Hanle Zhang, Pei Fan   +5 more
doaj   +1 more source

Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study

Journal of Blood Medicine, 2021
Giuseppe Cardillo,1 Giuseppe Vito Viggiano,2 Vincenzo Russo,3 Sara Mangiacapra,4 Antonella Cavalli,5 Giampiero Castaldo,2 Federica Agrusta,2 Annamaria Bellizzi Snr,5 Maria Amitrano Snr,4 Mariateresa Iannuzzo,6 Clara Sacco,7 Corrado Lodigiani,7 Andrea ...
Cardillo G, Viggiano GV, Russo V, Mangiacapra S, Cavalli A, Castaldo G, Agrusta F, Bellizzi Snr A, Amitrano Snr M, Iannuzzo M, Sacco C, Lodigiani C, Fontanella A, Di Micco P   +13 more
doaj  

Fondaparinux used for severe heparin induced thrombocytopenia with subacute instent thrombosis [PDF]

, 2008
Heparin induced thrombocytopenia (HIT) is an immune mediated event that may result in life and limb threatening complications. We report a 52 year old diabetic woman with subacute instent thrombosis and severe heparin induced thrombocytopenia treated ...
Çeneli, Özcan, Şimşek, Vedat, Doğru, Mehmet Tolga, Ebinç, Haksun, Özer, Murat, Tulmaç, Murat   +5 more
core  

Absence of Placental Transfer of Pentasaccharide (Fondaparinux, Arixtra®) in the Dually Perfused Human Cotyledon in vitro

, 2002
SummaryThe synthetic pentasaccharide, fondaparinux, is the first of a new antithrombotic class: selective factor Xa inhibitors. Comparative clinical trials of fondaparinux versus heparins in prevention and treatment of venous thromboembolism are ongoing.
C. Vergnes, B. Banwarth, T. Nadal, M.C. Saux, F. Lagrange, J.L. Brun, J.J. Leng, F. Paolucci   +7 more
core   +1 more source

Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice

, 2010
SummaryFondaparinux is a synthetic antithrombotic agent with specific anti-factor Xa activity. A population pharmacokinetic model of fondaparinux, based on data obtained in patients included in phase II/III trials, has been described.
Beatrice Deygas, Silvy Laporte, Michaela Fontenay, null null, Denis Baylot, Jeanne-Yvonne Borg, Paul Zufferey, Philippe Nguyen, Patrick Mismetti, Xavier Delavenne   +9 more
core   +1 more source

Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin

, 2005
Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating IgG antibodies that recognize platelet factor 4 (PF4) bound to heparin. Immunogenicity of heparins differs in that unfractionated heparin (UFH) induces more anti-PF4/heparin ...
Kelton, J. G., Marder, V. J., Eriksson, Bengt I.,, Moore, J. C., Greinacher, A., Warkentin, T. E., Cook, R. J., Sheppard, J. A.   +7 more
core  

Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives

, 2011
Heparin derivative-based therapy has evolved from unfractionated heparin (UFH) to low-molecular-weight heparins (LMWHs) and now fondaparinux, a synthetic pentasaccharide. Contrary to UFH or LMWHs, fondaparinux is not neutralized by protamine sulfate, and
Judicael Fazavana, Elsa P. Bianchini, Delphine Borgel, Veronique Picard   +3 more
core   +1 more source